6.49MMarket Cap-0.62P/E (TTM)
1.486High1.410Low100.69KVolume1.410Open1.410Pre Close146.41KTurnover2.35%Turnover RatioLossP/E (Static)4.39MShares11.70052wk High1.06P/B6.33MFloat Cap1.00052wk Low--Dividend TTM4.28MShs Float3417.576Historical High--Div YieldTTM5.36%Amplitude1.000Historical Low1.454Avg Price1Lot Size
Intelligent Bio Solutions Stock Forum
Benzinga· 4 mins ago
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...
Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results
Intelligent Bio Solutions (INBS) has successfully completed its method comparison study for the Intelligent Fingerprinting Drug Screening System, achieving 94.1% accuracy, 82.2% sensitivity, and 100% specificity.
The study, conducted with CenExel using 135 healthy donors and nine system operators, compared fingerprint sweat opiate screening t...
GlobeNewswire· 08:308
Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024
INBS will include data from recent PK study alongside results of method comparison study in 510(k) submission
Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection
FDA 510(k) Clearance Would Enable the Introduction of INBS' Technology to the US in 2025
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights
Positive
Revenue increased 10% YoY and 20% QoQ to $0.87M
Higher-margin cartridge sales now exceed reader revenue
Secured 22 new accounts with combined 152,000 employee headcount
International sales increased by 15%
Completed in-clinic portion of FDA 510(k) study
Negative
Net loss increased to $2.70M from $2.43M YoY
Cash position decreased to $3.9...
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
Intelligent Bio Solutions (Nasdaq: INBS) has partnered with B2i Digital to launch an investor-focused marketing campaign. The initiative aims to raise awareness of INBS' patented drug screening technology, which provides a non-invasive alternative to traditional drug tests. B2i Digital will implement digital marketing strategies to highlight the company's Intelligent Fingerp...
1 MINUTE AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
Benzinga· 4 mins ago
Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer ...
No comment yet